The rise of thyroid cancer incidence in adolescents and young adults
Menée à partir des données GLOBOCAN, cette étude internationale estime, dans 185 pays pour l'année 2022, l'incidence du cancer de la thyroïde et la mortalité spécifique chez les adolescents et jeunes adultes (âge : 15-39 ans)
In The Lancet Diabetes & Endocrinology, Mengmeng Li and colleagues analysed global trends in thyroid cancer incidence from 2003 to 2017 and contemporary burden for the year 2022 among adolescents and young adults (AYAs; aged 15 to 39 years),1 extending previous studies in older adult populations. Using validated methods and data from the Cancer Incidence in Five Continents Plus and from the Global Cancer Observatory databases, the authors observed increasing incidence trends in nearly all of the 185 included countries, with average annual percent changes exceeding 10% in six. In 2022, the age-standardized rate (ASR) of thyroid cancer incidence was 11·0 per 100 000 females and 3·8 per 100 000 males globally. This high incidence rate has made thyroid cancer the second most diagnosed cancer among female AYAs, after breast cancer, and the leading cancer diagnosis among male AYAs worldwide. Notably, the increase in thyroid cancer incidence has been documented across all adolescent and young adult age groups, but no increase has been reported in children under 10 years of age.
The Lancet Diabetes & Endocrinology , commentaire, 2025